BBS9

Across TCGA pan-cancer cohorts, BBS9 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated BBS9 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher BBS9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BBS9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

READ, LUAD, and UCEC are the cancer types where BBS9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.184	0.853	<.001	21	view →
LUAD	OS	Median	All	0.159	0.791	<.001	18	view →
UCEC	DFS	Median	All	0.931	0.615	.011	10	view →
ESCA	DFS	Median	III,IV	0.100	0.442	.003	9	view →
SKCM	DFS	Median	II,III,IV	1.000	0.667	.022	7	view →
TGCT	DFS	Median	All	0.066	0.802	<.001	6	view →
GBM	DFS	Median	All	0.043	0.243	.003	6	view →
BLCA	OS	Median	III,IV	1.000	0.349	.016	6	view →
HNSC	OS	Median	All	0.154	0.412	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

BBS9–READ (DFS)

Open the READ breakdown →